Connect Biopharma to Present a Late-Breaking Abstract at the American Thoracic Society (ATS) 2024 International Conference on the Positive Results from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma

May 7, 2024

https://www.globenewswire.com/news-release/2024/05/07/2876480/0/en/Connect-Biopharma-to-Present-a-Late-Breaking-Abstract-at-the-American-Thoracic-Society-ATS-2024-International-Conference-on-the-Positive-Results-from-the-Global-Phase-2b-Trial-of-R.html

SAN DIEGO, CA and TAICANG, China, May 07, 2024 (GLOBE NEWSWIRE) — Connect Biopharma Holdings Limited (Nasdaq:CNTB) (“Connect Biopharma” or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, today announced data from its global Phase 2b trial of rademikibart in patients with moderate-to-severe asthma was accepted as a late-breaking abstract for poster presentation at the upcoming ATS 2024 International Meeting being held May 17-22, 2024 in San Diego, CA.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.